Abstract
AbstractDespite prolonged surveillance and interventions, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses continue to pose a severe global health burden. Thus, we developed a chimpanzee adenovirus-based combination vaccine, AdC68-HATRBD, with dual specificity against SARS-CoV-2 and influenza virus. When used as a standalone vaccine, intranasal immunization with AdC68-HATRBD induced comprehensive and potent immune responses consisting of immunoglobin (Ig) G, mucosal IgA, neutralizing antibodies, and memory T cells, which protected the mice from BA.5.2 and pandemic H1N1 infections. When used as a heterologous booster, AdC68-HATRBD markedly improved the protective immune response of the licensed SARS-CoV-2 or influenza vaccine. Therefore, whether administered intranasally as a standalone or booster vaccine, this combination vaccine is a valuable strategy to enhance the overall vaccine efficacy by inducing robust systemic and mucosal immune responses, thereby conferring dual lines of immunological defenses for these two viruses.
Funder
National Natural Science Foundation of China
National Science Foundation of China | Key Programme
Science and Technology Commission of Shanghai Municipality
Department of Science and Technology of Sichuan Province
Publisher
Springer Science and Business Media LLC
Reference80 articles.
1. Javanian, M. et al. A brief review of influenza virus infection. J. Med. Vroly. 93, 4638–4646 (2021).
2. WHO. Influenza (Seasonal) Fact Sheet https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) (2023).
3. Suthar, A. B. et al. Public health impact of covid-19 vaccines in the US: observational study. Bmj 377, e069317 (2022).
4. Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162–177 (2023).
5. WHO. WHO Roadmap On Uses Of COVID-19 Vaccines In The Context Of Omicron And High Population Immunity. https://iris.who.int/bitstream/handle/10665/373987/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2-eng.pdf?sequence=1 (2023).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献